Watson Pharma shares spike on removal of FDA plant ban (AP via Yahoo! Finance)
Shares of Watson Pharmaceuticals spiked nearly 7 percent Tuesday, after the Food and Drug Administration ended its years-long scrutiny of the drug maker's Davie, Fla., manufacturing plant, allowing products made there to be eligible for FDA approval.

Generic penicillins: boosted by FDA's back-to-basics for S.pneumoniae (Pharmaceutical Business Review)
According to the Infectious Disease Society of North America, the FDA has changed the breakpoints used to determine the susceptibility cut-off for penicillins in the treatment of Streptococcus pneumoniae pneumonia. This will reinvigorate this largely genericized antibiotic class, and is indicative of increasing pressure on antibiotics as efforts are made to restrict antibiotic resistance.